HST Global, Inc. (HSTC)
USD 0.59
(0.0%)
USD 0.59
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -140.9 Thousand USD | 0.09% |
| 2022 | -141.03 Thousand USD | 3.21% |
| 2021 | -145.71 Thousand USD | 29.94% |
| 2020 | -207.97 Thousand USD | -37.23% |
| 2019 | -151.55 Thousand USD | -6.29% |
| 2018 | -142.58 Thousand USD | 6.8% |
| 2017 | -152.99 Thousand USD | -11.45% |
| 2016 | -137.27 Thousand USD | 14.23% |
| 2015 | -160.04 Thousand USD | -7.45% |
| 2014 | -148.95 Thousand USD | 5.33% |
| 2013 | -157.34 Thousand USD | 54.01% |
| 2012 | -342.15 Thousand USD | 32.14% |
| 2011 | -504.23 Thousand USD | 32.95% |
| 2010 | -751.98 Thousand USD | 42.86% |
| 2009 | -1.31 Million USD | 13.03% |
| 2008 | -1.51 Million USD | -954.7% |
| 2007 | -143.48 Thousand USD | 94.06% |
| 2006 | -2.41 Million USD | -108.69% |
| 2005 | -1.15 Million USD | -1699.28% |
| 2004 | -64.35 Thousand USD | 64.8% |
| 2003 | -182.82 Thousand USD | -66.85% |
| 2002 | -109.57 Thousand USD | 75.13% |
| 2001 | -440.63 Thousand USD | 73.46% |
| 2000 | -1.66 Million USD | -730.0% |
| 1999 | -200 Thousand USD | -100.0% |
| 1998 | -100 Thousand USD | 81.82% |
| 1997 | -550 Thousand USD | 57.69% |
| 1996 | -1.3 Million USD | -8.33% |
| 1995 | -1.2 Million USD | -500.0% |
| 1994 | -200 Thousand USD | 50.0% |
| 1993 | -400 Thousand USD | 60.0% |
| 1992 | -1 Million USD | -150.0% |
| 1991 | -400 Thousand USD | -233.33% |
| 1990 | 300 Thousand USD | 50.0% |
| 1989 | 200 Thousand USD | 200.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -16.56 Thousand USD | 49.35% |
| 2024 Q1 | -32.68 Thousand USD | 7.84% |
| 2023 FY | -140.91 Thousand USD | 0.09% |
| 2023 Q1 | -38.07 Thousand USD | -10.08% |
| 2023 Q4 | -35.47 Thousand USD | -3.21% |
| 2023 Q3 | -34.36 Thousand USD | -4.18% |
| 2023 Q2 | -32.99 Thousand USD | 13.36% |
| 2022 Q4 | -34.58 Thousand USD | -0.0% |
| 2022 Q2 | -34.52 Thousand USD | 7.52% |
| 2022 Q1 | -37.33 Thousand USD | -7.9% |
| 2022 FY | -141.03 Thousand USD | 3.21% |
| 2022 Q3 | -34.58 Thousand USD | -0.17% |
| 2021 Q3 | -34.59 Thousand USD | 9.47% |
| 2021 Q4 | -34.59 Thousand USD | -0.0% |
| 2021 Q2 | -38.21 Thousand USD | 0.23% |
| 2021 FY | -145.71 Thousand USD | 29.94% |
| 2021 Q1 | -38.3 Thousand USD | 59.53% |
| 2020 Q3 | -34.68 Thousand USD | 20.86% |
| 2020 Q4 | -94.65 Thousand USD | -172.93% |
| 2020 Q1 | -34.81 Thousand USD | -36.65% |
| 2020 Q2 | -43.82 Thousand USD | -25.86% |
| 2020 FY | -207.97 Thousand USD | -37.23% |
| 2019 Q4 | -25.48 Thousand USD | 53.68% |
| 2019 Q3 | -55 Thousand USD | -58.26% |
| 2019 Q2 | -34.75 Thousand USD | 4.27% |
| 2019 Q1 | -36.3 Thousand USD | -4.88% |
| 2019 FY | -151.55 Thousand USD | -6.29% |
| 2018 Q4 | -34.61 Thousand USD | 0.06% |
| 2018 Q1 | -37.87 Thousand USD | -10.5% |
| 2018 Q3 | -34.63 Thousand USD | 2.31% |
| 2018 Q2 | -35.45 Thousand USD | 6.39% |
| 2018 FY | -142.58 Thousand USD | 6.8% |
| 2017 Q3 | -31.11 Thousand USD | 10.08% |
| 2017 Q4 | -34.27 Thousand USD | -10.17% |
| 2017 FY | -152.99 Thousand USD | -11.45% |
| 2017 Q1 | -53 Thousand USD | -53.39% |
| 2017 Q2 | -34.59 Thousand USD | 34.73% |
| 2016 Q2 | -35.65 Thousand USD | -6.35% |
| 2016 Q1 | -33.52 Thousand USD | 13.87% |
| 2016 Q3 | -33.54 Thousand USD | 5.9% |
| 2016 FY | -137.27 Thousand USD | 14.23% |
| 2016 Q4 | -34.55 Thousand USD | -3.02% |
| 2015 Q3 | -32.48 Thousand USD | 10.37% |
| 2015 FY | -160.04 Thousand USD | -7.45% |
| 2015 Q4 | -38.91 Thousand USD | -19.8% |
| 2015 Q1 | -52.39 Thousand USD | -48.35% |
| 2015 Q2 | -36.24 Thousand USD | 30.83% |
| 2014 FY | -148.95 Thousand USD | 5.33% |
| 2014 Q3 | -37.83 Thousand USD | 1.56% |
| 2014 Q2 | -38.43 Thousand USD | -2.89% |
| 2014 Q1 | -37.35 Thousand USD | -12.0% |
| 2014 Q4 | -35.32 Thousand USD | 6.64% |
| 2013 Q3 | -37.14 Thousand USD | 33.26% |
| 2013 FY | -157.34 Thousand USD | 54.01% |
| 2013 Q4 | -33.35 Thousand USD | 10.2% |
| 2013 Q2 | -55.65 Thousand USD | -78.42% |
| 2013 Q1 | -31.19 Thousand USD | 61.56% |
| 2012 Q3 | -83.03 Thousand USD | 17.61% |
| 2012 Q4 | -81.15 Thousand USD | 2.26% |
| 2012 Q2 | -100.77 Thousand USD | -30.56% |
| 2012 Q1 | -77.19 Thousand USD | 67.52% |
| 2012 FY | -342.15 Thousand USD | 32.14% |
| 2011 Q1 | -85.63 Thousand USD | -14.55% |
| 2011 Q2 | -98.96 Thousand USD | -15.57% |
| 2011 Q3 | -81.97 Thousand USD | 17.16% |
| 2011 Q4 | -237.66 Thousand USD | -189.91% |
| 2011 FY | -504.23 Thousand USD | 32.95% |
| 2010 Q4 | -74.75 Thousand USD | 51.95% |
| 2010 Q3 | -155.58 Thousand USD | 49.96% |
| 2010 Q2 | -310.9 Thousand USD | -38.64% |
| 2010 FY | -751.98 Thousand USD | 42.86% |
| 2010 Q1 | -224.24 Thousand USD | 29.54% |
| 2009 Q1 | -324.11 Thousand USD | -35.46% |
| 2009 FY | -1.31 Million USD | 13.03% |
| 2009 Q4 | -318.24 Thousand USD | -0.39% |
| 2009 Q3 | -317.01 Thousand USD | 11.14% |
| 2009 Q2 | -356.74 Thousand USD | -10.07% |
| 2008 Q3 | -434.49 Thousand USD | 39.66% |
| 2008 FY | -1.51 Million USD | -954.7% |
| 2008 Q2 | -720.08 Thousand USD | -881.8% |
| 2008 Q1 | -73.34 Thousand USD | -65.78% |
| 2008 Q4 | -239.26 Thousand USD | 44.93% |
| 2007 Q3 | -99.24 Thousand USD | -144.95% |
| 2007 Q1 | -242.56 Thousand USD | 92.35% |
| 2007 Q4 | -44.24 Thousand USD | 55.42% |
| 2007 Q2 | 220.78 Thousand USD | 191.02% |
| 2007 FY | -143.48 Thousand USD | 94.06% |
| 2006 Q1 | -89.17 Thousand USD | 92.05% |
| 2006 Q2 | -29.2 Thousand USD | 67.25% |
| 2006 Q4 | -3.17 Million USD | -504.69% |
| 2006 Q3 | 783.5 Thousand USD | 2782.87% |
| 2006 FY | -2.41 Million USD | -108.69% |
| 2005 Q4 | -1.12 Million USD | -23163.13% |
| 2005 FY | -1.15 Million USD | -1699.28% |
| 2005 Q2 | -12.21 Thousand USD | -162.19% |
| 2005 Q3 | -4820.00 USD | 60.52% |
| 2005 Q1 | 19.63 Thousand USD | 165.63% |
| 2004 FY | -64.35 Thousand USD | 64.8% |
| 2004 Q4 | -29.91 Thousand USD | -56.68% |
| 2004 Q3 | -19.09 Thousand USD | -117.7% |
| 2004 Q2 | -8770.00 USD | -33.28% |
| 2004 Q1 | -6580.00 USD | 85.99% |
| 2003 Q1 | -8000.00 USD | -101.97% |
| 2003 Q2 | -15 Thousand USD | -87.5% |
| 2003 Q3 | -112.84 Thousand USD | -652.32% |
| 2003 Q4 | -46.97 Thousand USD | 58.37% |
| 2003 FY | -182.82 Thousand USD | -66.85% |
| 2002 Q4 | 406.27 Thousand USD | 212.34% |
| 2002 Q2 | -136.26 Thousand USD | -668.4% |
| 2002 Q1 | -17.73 Thousand USD | 98.4% |
| 2002 Q3 | -361.65 Thousand USD | -165.41% |
| 2002 FY | -109.57 Thousand USD | 75.13% |
| 2001 FY | -440.63 Thousand USD | 73.46% |
| 2001 Q4 | -1.11 Million USD | -5450.0% |
| 2001 Q3 | -20 Thousand USD | 0.0% |
| 2001 Q2 | -20 Thousand USD | -100.0% |
| 2001 Q1 | -10 Thousand USD | 99.13% |
| 2000 Q4 | -1.15 Million USD | -2400.0% |
| 2000 Q3 | 50 Thousand USD | 109.43% |
| 2000 Q2 | -530 Thousand USD | -1666.67% |
| 2000 Q1 | -30 Thousand USD | 50.0% |
| 2000 FY | -1.66 Million USD | -730.0% |
| 1999 Q3 | - USD | 100.0% |
| 1999 Q2 | -90 Thousand USD | -50.0% |
| 1999 Q4 | -60 Thousand USD | 0.0% |
| 1999 FY | -200 Thousand USD | -100.0% |
| 1999 Q1 | -60 Thousand USD | -185.71% |
| 1998 FY | -100 Thousand USD | 81.82% |
| 1998 Q4 | 70 Thousand USD | 158.33% |
| 1998 Q3 | -120 Thousand USD | -271.43% |
| 1998 Q2 | 70 Thousand USD | 158.33% |
| 1998 Q1 | -120 Thousand USD | -140.0% |
| 1997 Q1 | -200 Thousand USD | 84.62% |
| 1997 Q4 | -50 Thousand USD | 86.84% |
| 1997 Q3 | -380 Thousand USD | -192.31% |
| 1997 FY | -550 Thousand USD | 57.69% |
| 1997 Q2 | -130 Thousand USD | 35.0% |
| 1996 Q3 | 100 Thousand USD | 200.0% |
| 1996 FY | -1.3 Million USD | -8.33% |
| 1996 Q1 | -300 Thousand USD | 50.0% |
| 1996 Q2 | -100 Thousand USD | 66.67% |
| 1996 Q4 | -1.3 Million USD | -1400.0% |
| 1995 Q1 | 100 Thousand USD | 100.86% |
| 1995 Q4 | -600 Thousand USD | 14.29% |
| 1995 Q3 | -700 Thousand USD | -600.0% |
| 1995 Q2 | -100 Thousand USD | -200.0% |
| 1995 FY | -1.2 Million USD | -500.0% |
| 1994 Q4 | -11.6 Million USD | -390.0% |
| 1994 Q1 | 300 Thousand USD | 50.0% |
| 1994 FY | -200 Thousand USD | 50.0% |
| 1994 Q2 | - USD | -100.0% |
| 1994 Q3 | 4 Million USD | 0.0% |
| 1993 Q2 | -200 Thousand USD | -100.0% |
| 1993 Q1 | -100 Thousand USD | 85.71% |
| 1993 FY | -400 Thousand USD | 60.0% |
| 1993 Q3 | -200 Thousand USD | 0.0% |
| 1993 Q4 | 200 Thousand USD | 200.0% |
| 1992 FY | -1 Million USD | -150.0% |
| 1992 Q1 | 200 Thousand USD | 150.0% |
| 1992 Q2 | -100 Thousand USD | -150.0% |
| 1992 Q3 | -200 Thousand USD | -100.0% |
| 1992 Q4 | -700 Thousand USD | -250.0% |
| 1991 Q4 | -400 Thousand USD | -300.0% |
| 1991 Q1 | 100 Thousand USD | -66.67% |
| 1991 FY | -400 Thousand USD | -233.33% |
| 1991 Q3 | -100 Thousand USD | -200.0% |
| 1991 Q2 | 100 Thousand USD | 0.0% |
| 1990 Q1 | -100 Thousand USD | 0.0% |
| 1990 Q2 | 200 Thousand USD | 300.0% |
| 1990 Q3 | -100 Thousand USD | -150.0% |
| 1990 Q4 | 300 Thousand USD | 400.0% |
| 1990 FY | 300 Thousand USD | 50.0% |
| 1989 Q4 | -100 Thousand USD | -200.0% |
| 1989 FY | 200 Thousand USD | 200.0% |
| 1989 Q1 | 1.6 Million USD | 141.03% |
| 1989 Q2 | 100 Thousand USD | -93.75% |
| 1989 Q3 | 100 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Regen BioPharma, Inc. | -686.95 Thousand USD | 79.488% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 17.843% |
| CytoDyn Inc. | -18.05 Million USD | 99.22% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.761% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -19394.335% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 92.242% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 97.207% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -370.443% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 22.359% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 98.548% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.746% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.814% |
| Resverlogix Corp. | -12.74 Million USD | 98.895% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 63.83% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 101.446% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 94.261% |
| Mesoblast Limited | -84.14 Million USD | 99.833% |
| GB Sciences, Inc. | -1.42 Million USD | 90.081% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 79.488% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 99.21% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 95.862% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 97.88% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 95.553% |
| ContraFect Corporation | -56.88 Million USD | 99.752% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 94.878% |
| BioStem Technologies, Inc. | -7.77 Million USD | 98.189% |
| LadRx Corporation | -3.82 Million USD | 96.315% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.112% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 87.408% |
| CSL Limited | 3.7 Billion USD | 100.004% |
| Biomind Labs Inc. | -1 Million USD | 86.043% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 84.871% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.172% |
| Nascent Biotech, Inc. | -2.22 Million USD | 93.681% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.804% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 102.867% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 103.98% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 90.827% |
| Marizyme, Inc. | -34.08 Million USD | 99.587% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 98.312% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 75.048% |
| Zenith Capital Corp. | -8.94 Million USD | 98.424% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 95.057% |
| Halberd Corporation | -75.05 Thousand USD | -87.751% |
| Genus plc | 6.4 Million USD | 102.202% |
| Pharming Group N.V. | -4.87 Million USD | 97.112% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 92.907% |
| IMV Inc. | -38.67 Million USD | 99.636% |
| Affymax, Inc. | -15.04 Million USD | 99.063% |
| SYBLEU INC | -149.18 Thousand USD | 5.546% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 86.503% |
| Enzolytics Inc. | -2.14 Million USD | 93.443% |
| argenx SE | -425.04 Million USD | 99.967% |
| AVAX Technologies, Inc. | 6.69 Million USD | 102.105% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 89.95% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 89.449% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 96.239% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -459.821% |
| Cell Source, Inc. | -4.32 Million USD | 96.742% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 70.83% |
| Q BioMed Inc. | -3.44 Million USD | 95.911% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 96.675% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 88.781% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 94.637% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 96.906% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.744% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 95.143% |
| Rebus Holdings, Inc. | -664 Thousand USD | 78.779% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 85.681% |
| Skye Bioscience, Inc. | -13.67 Million USD | 98.969% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 92.442% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 92.971% |
| ONE Bio Corp. | 13.68 Million USD | 101.03% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 92.709% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 87.474% |
| Agentix Corp. | -1.37 Million USD | 89.728% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 95.173% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 91.078% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -708.834% |
| Kadimastem Ltd | -3.04 Million USD | 95.365% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 46.162% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 66.086% |
| NovAccess Global Inc. | -2.46 Million USD | 94.288% |
| Itoco Inc. | -919.14 Thousand USD | 84.67% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 35.974% |
| Qrons Inc. | -643.67 Thousand USD | 78.109% |
| Mobile Lads Corp. | -554.55 Thousand USD | 74.591% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.966% |
| International Stem Cell Corporation | -663 Thousand USD | 78.747% |
| Bioxytran, Inc. | -3.82 Million USD | 96.311% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -167.68% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -592.758% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 99.611% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 91.291% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 80.851% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 95.471% |
| Neutra Corp. | -229.48 Thousand USD | 38.599% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 99.197% |
| PureTech Health plc | -146.19 Million USD | 99.904% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 99.344% |
| IXICO plc | -1.43 Million USD | 90.194% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 98.515% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.884% |
| CSL Limited | 3.81 Billion USD | 100.004% |
| Cellectis S.A. | -108.85 Million USD | 99.871% |